glp 1 physiology informs the pharmacotherapy of obesity Frontiers Weight Reduction with GLP-1 Agonists

Its effectiveness can range from noticeable improvements to more subtle, preventative effects, depending on the individual's specific circumstances and lifestyle

HDAC6 as privileged target in drug discovery: a perspective

Cramp frequency and severity were higher in females of the present study, consistent with previous studies [3, 14, 15]

Similarly, in vivo studies based on rodents have shown reduced hepatic GHR expression (32) and GH binding (32, 33) following induction of diabetes, and that insulin treatment facilitated GH binding (33)

Several studies have demonstrated that silencing fat mass and obesity-associated protein (FTO) and iron regulatory protein 2 (IRP2) mitigates abnormalities in the amino acid antioxidant system and ferroptosis, thereby attenuating dopaminergic neuronal damage